Safer Pain Management Alternatives

Non-Opioid Analgesics and Neuromodulators

• For patients with pain, consider non-opioid analgesics when possible, and if neuromodulators are needed, consider TCAs or SNRIs which have analgesic properties without the cardiac risks of droperidol, as recommended by the American Gastroenterological Association 1

Abdominal Pain Management

• For patients with abdominal pain due to pyogenic liver abscess, consider acetaminophen (if liver function permits), NSAIDs (if renal function permits and no bleeding risk), and opioids without known QT prolongation effects for severe pain, and consider antispasmodics for cramping pain, according to the American Gastroenterological Association 1
• Initial evaluation should include clinical assessment for fever, right upper quadrant pain, and abnormal liver function tests, complete blood count, and imaging studies such as ultrasound (with 85.8% sensitivity) and CT scan with contrast (as the gold standard for definitive diagnosis), as recommended by the American Association for the Study of Liver Diseases and supported by evidence 2, 3, 4, 5

Diagnostic Imaging

• Ultrasound should be the first imaging modality used for the diagnosis of hepatic abscess, followed by CT scan with contrast for definitive characterization if needed, along with blood cultures before antibiotic initiation and abscess fluid culture through aspiration to guide antibiotic therapy, as recommended by the World Health Organization and supported by evidence 5, 6, 7
• MRI is useful when CT is contraindicated, particularly helpful for characterizing complex features, with a strength of evidence level of moderate 5
• 18FDG PET-CT should be considered in cases of suspected infected hepatic cysts or when diagnosis remains unclear, with a strength of evidence level of low 5
• ELISA tests for detecting anti-mannan antibodies have excellent sensitivity and specificity for amoebic liver abscess diagnosis, as recommended by the American Society of Tropical Medicine and Hygiene, with a strength of evidence level of high 4
• Tumor markers (such as generic tumor markers) can be used to exclude neoplastic cysts, with a sensitivity and specificity of 90% and 80%, respectively 5

Antibiotic Therapy

• The choice of oral antibiotic should be guided by culture results whenever possible, with adjustments made based on susceptibility testing to ensure optimal coverage against the identified pathogens 8
• Fluoroquinolones (ciprofloxacin) + metronidazole is a first-line oral therapy option 8
• The World Journal of Emergency Surgery recommends Amoxicillin/Clavulanate 2 g/0.2 g q8h as a first-line option for treatment, and for patients with beta-lactam allergy, Eravacycline 1 mg/kg q12h or Tigecycline 100 mg loading dose then 50 mg q12h are recommended as alternative first-line options, with a strength of evidence level of moderate 7
• The World Health Organization recommends the use of piperacilina/tazobactam, imipenem/cilastatin, meropenem, ertapenem, or aztreonam as first-line therapy for the management of hepatic abscess of colangitic origin, with ampicilina-sulbactam 3 grams every 6 hours with metronidazol as an acceptable alternative, with a strength of evidence level of high 9
• The American Association for the Study of Liver Diseases recommends first-line empirical therapy with Amoxicillin/clavulanate or Piperacillin/tazobactam, depending on patient condition, with alternative regimens including third-generation cephalosporins plus metronidazole for non-critical, immunocompetent patients and critical or immunocompromised patients, respectively, with a strength of evidence level of moderate 2

Treatment Guidelines

Drainage and Management

• Pigtail catheters should be inserted at the optimal site guided by ultrasound, and small-bore percutaneous drains are preferred over large-bore surgical drains to minimize patient discomfort, after insertion, a chest/abdominal radiograph should be performed to confirm proper placement, and the drain should be connected to a unidirectional flow drainage system kept below the level of the patient's body, with a strength of evidence level of moderate 12
• Remove the drain once there is clinical resolution and when the patient becomes afebrile, drainage is less than 10 ml in 24 hours, and follow-up imaging shows negligible residual cavity, with a strength of evidence level of low 12
• The treatment duration should be at least 4 days after adequate source control, and up to 7 days based on clinical conditions and inflammation indices, with the following recommended treatment durations:

Monitoring and Follow-up

• Monitor treatment efficacy through resolution of clinical symptoms, normalization of laboratory values, and follow-up imaging to assess abscess resolution, and for recurrent infections, evaluate for underlying causes such as biliary obstruction, foreign bodies, or immunocompromised state, with a strength of evidence level of moderate 12
• Reevaluation of the diagnosis, consideration of antibiotic resistance, and evaluation of surgical drainage or change of antibiotic regimen are necessary in cases of persistence of fever >72 hours after initiation of antibiotics and drainage, increase in abscess size on imaging studies, or clinical deterioration or appearance of complications (rupture, peritonitis), with a strength of evidence level of high 9
• No routine follow-up imaging is recommended after successful treatment, with a strength of evidence level of low 5

Amebic Liver Abscess Treatment

• The use of a luminal agent, such as paromomycin, is required after tissue amebicide treatment to eliminate intestinal colonization and prevent relapse, as suggested by guidelines from relevant medical societies, with a strength of evidence level of moderate 10
• The typical duration of paromomycin treatment is 7 days when used after metronidazole or tinidazole, with a strength of evidence level of low 13
• For adults, the recommended dosage of paromomycin is 25-35 mg/kg body weight/day orally in 2-4 divided doses, with a maximum dose of 500 mg four times daily, as suggested by the CDC, with a strength of evidence level of high 14
• The Centers for Disease Control and Prevention recommends a dosage of 30 mg/kg/day of Metronidazole for children for 5-10 days, with a strength of evidence level of moderate 15